The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.
Kanvas Bio Unveils Clinical Data on the Gut Microbiome’s Impact on Anti-Tumoral Immunity at SITC ...
Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...
Two first-line cutaneous melanoma patients - one patient who was dose escalated from 70 mg to 210 mg and finally to 350 mg experienced a confirmed partial response (PR) at the higher dose; one patient ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment ...
BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback